Freeland G R, Northington R S, Hedrich D A, Walker B R
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia 19104.
Clin Pharmacol Ther. 1988 May;43(5):473-9. doi: 10.1038/clpt.1988.61.
We evaluated the potential hepatic toxicity of ibuprofen, aspirin, and oxaprozin in 1468 patients with rheumatoid arthritis and osteoarthritis by slightly modifying an algorithm that was developed to evaluate the drug relatedness of renal toxicity associated with therapeutic doses of these agents in the same population. Ibuprofen proved to be the safest of these nonsteroidal antiinflammatory drugs; it was associated with no AST elevation that was considered probably drug related as determined by application of the algorithm to laboratory values and information from case report forms. The frequency of probably drug-related AST elevations was highest (5%) with aspirin; with oxaprozin, an investigational nonsteroidal antiinflammatory drug, the incidence (3%) fell between that for the other two agents. Thus our findings on the hepatic safety of ibuprofen are consistent with those in the medical literature.
我们通过对一种算法稍作修改,评估了布洛芬、阿司匹林和恶丙嗪在1468例类风湿性关节炎和骨关节炎患者中的潜在肝毒性。该算法最初是为评估同一人群中这些药物治疗剂量相关肾毒性的药物关联性而开发的。布洛芬被证明是这些非甾体抗炎药中最安全的;根据该算法应用于实验室值和病例报告表信息所确定,它与任何被认为可能与药物相关的AST升高均无关联。阿司匹林导致可能与药物相关的AST升高的频率最高(5%);恶丙嗪作为一种研究性非甾体抗炎药,其发生率(3%)介于其他两种药物之间。因此,我们关于布洛芬肝安全性的研究结果与医学文献中的结果一致。